Table 1.

Nucleoside analog of molnupiravir for the treatment of COVID-19. Status in November 2020.

Nucleoside drug	From	Mechanism of action	In vitro activity EC50[µM]	Animal model efficacy	Clinical dosing
Molnupiravir (EIDD-2801; MK-4482)	Nucleoside prodrug	Viral RNA mutagenesis	0.05–0.3	Mouse	Oral BID 200–800  mg